APHA – Aphria Inc.

Stock Forums Stocks Forum NYSE Stocks APHA – Aphria Inc.

This topic contains 4 replies, has 1 voice, and was last updated by  Stocks News Feed 3 weeks ago.

Viewing 4 replies - 1 through 4 (of 4 total)
  • Author
    Replies
  • #273447

    APHA – Aphria Secures Cannabis Cultivation License in Germany

    #255552

    APHA – Aphria Awarded Provisional Approval in Germany for Cannabis Cultivation License
    Leamington, Ontario – April 5, 2019 – Aphria Inc. (“Aphria” or the “Company”) (TSX:APHA and NYSE:APHA) today announced that its German subsidiary Aphria Deutschland GmbH (“Aphria Germany”) has been selected by the German Federal Institute for Drugs and Medical Devices (“BfArM”) to receive a license for the domestic cultivation of medical cannabis. The provisional decision announced by BfArM is subject to a mandatory 10-day standstill period for public contracts (the “Standstill”), which permits unsuccessful bidders to challenge the decision before the final contract is signed. BfArM’s decision would grant Aphria 5 of the 13 available lots, each with a minimum annual capacity of 200 kg.
    “Aphria is proud to have been selected as a successful applicant in the German tender process, a testament to our high production quality standards,” said Hendrik Knopp, Managing Director of Aphria Germany. “The decision from BfArM is a validation of our strategic approach to supporting the German medical cannabis market, including with high-quality, domestic production to secure vital supply for patients. We are very pleased with our continued business momentum in Germany.”

    Since Germany’s Cannabis as Medicines Act was enacted in March 2017, the country’s growing medical cannabis needs, currently estimated at up to 40,000 patients, has been exclusively supplied by imports. Pending the successful completion of the Standstill, Aphria looks forward to supplying German patients with domestically-grown, high-quality medical cannabis.

    We Have a Good Thing Growing
    About Aphria
    Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

    For more information, visit http://www.aphria.ca

    ###
    For media inquiries please contact:
    Tamara Macgregor
    Vice President, Communications
    tamara.macgregor@aphria.com
    437-343-4000

    For investor inquiries please contact:
    Katie M. Turner
    ICR, Inc.
    katie.turner@icrinc.com
    646-277-1228

    #255450

    APHA – Aphria Awarded Provisional Approval in Germany for Cannabis Cultivation License

    #247313

    APHA – Aphria Introduces CannRelief, a CBD-Based Nutraceutical and Cosmetics Product Line, for the German Market
    CannRelief CBD oils are the first product among many to be launched as part of the skincare and cosmetic product line
    Leamington, Ontario – April 1, 2019 – Aphria Inc. (“Aphria” or the “Company”) (TSX: APHA and NYSE: APHA) through its subsidiary Aphria Deutschland GmbH (“Aphria Germany”) today launched the Company’s first CBD-based nutraceutical, the first product in its CBD-based cosmetics line for the German market. Featuring CBD derived from hemp, the CannRelief brand of products are being produced in the European Union and distributed by the Company’s subsidiary, CC Pharma, which has access to more than 13,000 pharmacies throughout Germany.

    “We are excited to introduce our first brand of CBD products for the German nutraceutical and cosmetics market,” said Jakob Ripshtein, President of Aphria. “Supported by our extensive distribution network through CC Pharma, CannRelief provides a natural extension to Aphria’s growing business opportunities in the German medical cannabis market. We look forward to providing a full range of CannRelief CBD products this year.”

    CannRelief CBD oils are being sold in both a 5% and 10% CBD concentration and can be found in select stores across Germany. A range of skincare and other products, including creams, serums and masks will be introduced under the CannRelief brand in a phased rollout in 2019. More information about CannRelief products can be found at cannrelief.de.

    “Aphria continues to execute on its strategic growth initiatives in Germany,” continued Ripshtein. “We believe we have tremendous momentum in Germany and across our international business as we continue to strengthen our global footprint.”

    We Have a Good Thing Growing.
    About Aphria
    Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.

    For more information, visit aphria.ca

    ###
    For media inquiries please contact:
    Tamara Macgregor
    Vice President, Communications
    tamara.macgregor@aphria.com
    437-343-4000

    For investor inquiries please contact:
    Katie M. Turner
    ICR, Inc.
    katie.turner@icrinc.com
    646-277-1228
    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, estimated margins, expectations with respect to actual volumes under the agreement, expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with respect to future production costs. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

    Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Viewing 4 replies - 1 through 4 (of 4 total)

You must be logged in to reply to this topic. Login Register




Done Reading? You might also find these links useful:
Stock Market News | Stocks Catalyst Calendar | Social Activity Stream | Stock Forums | Social Stock Groups